Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints
The positive outcomes from the late-stage clinical trial of JS005 may enhance Junshi Biosciences’ market potential and support future revenue growth b...
Read Full Article →